secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-036847
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved
--------------------------------------------------------------------------------

- Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.
- Cash and equivalents $271.2M at Dec 31, 2023; plus $81.1M net IPO proceeds in Feb 2024.
- Hemophilia A program achieved NHP proof of concept; development candidate nomination expected mid-2024.
- Demonstrated CAST system for >10,000 bp targeted integrations and SMART base editors as small as 623 amino acids.
- Cash runway supports 2 INDs and 2 additional development candidate nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/0000950170-24-036847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/mgx-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-036847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer